IP Library Granted Patent US 8,420,590
Granted Patent B2
US 8,420,590 · App. 12/516,961 · Granted Apr 16, 2013

Genes and proteins that home to developing microvessels

Inventors: Anton Wellstein (Washington, DC); Marcel O. Schmidt (Washington, DC); Stephan Zbinden (Wabern, CH); Mary Susan Burnett (Fairfax, VA); Stephen E. Epstein (Rockville, MD)
Assignees: Georgetown University; MedStar Health Research Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,590
App. No.
12/516,961
Granted
Apr 16, 2013
Kind
B2
Abstract

Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia.

Claims (8)

1. A developing vessel homing polypeptide comprising the amino acid sequence PTLAVYSPHRLVMFIFIMIRKKHHFLLWLYAYFM (amino acid residues 14-47 of SEQ ID NO: 18).

2. The homing polypeptide of claim 1 coupled to a therapeutic moiety.

3. The homing polypeptide of claim 2 , wherein the therapeutic moiety is ricin, a radioisotope, a clotting agent, a thrombolytic factor, a chemotherapeutic agent, a radiosensitizing agent, an anti-angiogenesis agent, an anti-motility agent or an immunomodulatory agent.

4. A pharmaceutical composition comprising (a) the homing polypeptide of claim 1 , (b) a therapeutic agent and (c) a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 , wherein the therapeutic agent enhances collateral development or decreases microvasculature development.

6. A pharmaceutical composition comprising (a) the homing polypeptide of claim 1 coupled to a therapeutic moiety and (b) a pharmaceutically acceptable carrier.

7. A kit comprising the homing polypeptide of claim 1 .

8. The homing polypeptide of claim 1 encoded by SEQ ID NO:7.

Assignments (3)
CHANGE OF NAME Recorded Mar 13, 2013
From: MEDSTAR RESEARCH INSTITUTE
To: MEDSTAR HEALTH RESEARCH INSTITUTE, INC.
Reel/Frame 029990/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2010
From: WELLSTEIN, ANTON; SCHMIDT, MARCEL O.
To: GEORGETOWN UNIVERSITY
Reel/Frame 024048/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2010
From: EPSTEIN, STEPHEN E.; BURNETT, MARY SUSAN; ZBINDEN, STEPHAN
To: MEDSTAR RESEARCH INSTITUTE
Reel/Frame 024048/0776 →
Continuity (3)
Provisional Application 60872210 · Dec 1, 2006
Provisional Application 60899899 · Feb 6, 2007
Related Publication 20100216704A1 · Aug 26, 2010